244 related articles for article (PubMed ID: 2177496)
1. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Three-year experience with human cytomegalovirus infections in heart transplant recipients.
Grossi P; Revello MG; Minoli L; Percivalle E; Zavattoni M; Poma G; Martinelli L; Gerna G
J Heart Transplant; 1990; 9(6):712-9. PubMed ID: 2177498
[TBL] [Abstract][Full Text] [Related]
4. Early diagnosis and effective treatment of pulmonary CMV infection after lung transplantation.
Steinhoff G; Behrend M; Wagner TO; Höper MH; Haverich A
J Heart Lung Transplant; 1991; 10(1 Pt 1):9-14. PubMed ID: 1848789
[TBL] [Abstract][Full Text] [Related]
5. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
6. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
7. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
9. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients.
Kaplan CS; Petersen EA; Icenogle TB; Copeland JG; Villar HV; Sampliner R; Minnich L; Ray CG
Arch Intern Med; 1989 Sep; 149(9):2095-100. PubMed ID: 2549896
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection in isolated lung transplantations.
Maurer JR; Tullis DE; Scavuzzo M; Patterson GA
J Heart Lung Transplant; 1991; 10(5 Pt 1):647-9. PubMed ID: 1659900
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
Merigan TC; Renlund DG; Keay S; Bristow MR; Starnes V; O'Connell JB; Resta S; Dunn D; Gamberg P; Ratkovec RM
N Engl J Med; 1992 Apr; 326(18):1182-6. PubMed ID: 1313549
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
18. [Cytomegalovirus infection in lung transplantation; current status, detection, prophylactic treatment].
Aoe M; Tao H; Yamane M; Toyooka S; Sano Y; Okazaki M; Date H
Kyobu Geka; 2007 Oct; 60(11):988-92. PubMed ID: 17926902
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.
Pollard RB
Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S97-102. PubMed ID: 2456512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
